Methods for inhibiting sterol absorption
AssigneeSchering Corporation
InventorWing-Kee Philip Cho
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Claims10
A method of treating a vascular condition associated with elevated sterol and/or stanol levels, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of:
- Weight
- percent of
- Ingredient
- ingredient
- Compound of Formula (II)
- 10
- Lactose monohydrate
- 55
- Microcrystalline cellulose
- 20
- Povidone
- 4
- Croscarmellose sodium
- 8
- Sodium lauryl sulfate
- 2
- Magnesium stearate
- 1
- Total
- 100
- wherein the compound represented by Formula (II) below is:
A method of treating diabetes in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of:
- Weight
- percent of
- Ingredient
- ingredient
- Compound of Formula (II)
- 10
- Lactose monohydrate
- 55
- Microcrystalline cellulose
- 20
- Povidone
- 4
- Croscarmellose sodium
- 8
- Sodium lauryl sulfate
- 2
- Magnesium stearate
- 1
- Total
- 100
- wherein the compound represented by Formula (II) below is:
A method of treating obesity in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of:
- Weight
- percent of
- Ingredient
- ingredient
- Compound of Formula (II)
- 10
- Lactose monohydrate
- 55
- Microcrystalline cellulose
- 20
- Povidone
- 4
- Croscarmellose sodium
- 8
- Sodium lauryl sulfate
- 2
- Magnesium stearate
- 1
- Total
- 100
- wherein the compound represented by Formula (II) below is:
A method of lowering a plasma sterol concentration of a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of:
- Weight
- percent of
- Ingredient
- ingredient
- Compound of Formula (II)
- 10
- Lactose monohydrate
- 55
- Microcrystalline cellulose
- 20
- Povidone
- 4
- Croscarmellose sodium
- 8
- Sodium lauryl sulfate
- 2
- Magnesium stearate
- 1
- Total
- 100
- wherein the compound represented by Formula (II) below is:
A method of treating a vascular condition associated with elevated sterol and/or stanol levels, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of:
- milligrams
- of
- Ingredient
- ingredient
- Compound of Formula (II)
- 10
- Lactose monohydrate
- 55
- Microcrystalline cellulose
- 20
- Povidone
- 4
- Croscarmellose sodium
- 8
- Sodium lauryl sulfate
- 2
- Magnesium stearate
- 1
- Total
- 100
- wherein the compound represented by Formula (II) below is:
A method of treating diabetes in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of:
- milligrams
- of
- Ingredient
- ingredient
- Compound of Formula (II)
- 10
- Lactose monohydrate
- 55
- Microcrystalline cellulose
- 20
- Povidone
- 4
- Croscarmellose sodium
- 8
- Sodium lauryl sulfate
- 2
- Magnesium stearate
- 1
- Total
- 100
- wherein the compound represented by Formula (II) below is:
A method of treating obesity in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of:
- milligrams
- of
- Ingredient
- ingredient
- Compound of Formula (II)
- 10
- Lactose monohydrate
- 55
- Microcrystalline cellulose
- 20
- Povidone
- 4
- Croscarmellose sodium
- 8
- Sodium lauryl sulfate
- 2
- Magnesium stearate
- 1
- Total
- 100
- wherein the compound represented by Formula (II) below is:
A method of lowering a plasma sterol concentration of a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of:
- milligrams
- of
- Ingredient
- ingredient
- Compound of Formula (II)
- 10
- Lactose monohydrate
- 55
- Microcrystalline cellulose
- 20
- Povidone
- 4
- Croscarmellose sodium
- 8
- Sodium lauryl sulfate
- 2
- Magnesium stearate
- 1
- Total
- 100
- wherein the compound represented by Formula (II) below is:
Dependencies are inferred from the claim text.